Inhibitory activities of kukoamines A and B from Lycii Cortex on amyloid aggregation related to Alzheimer’s disease and type 2 diabetes

  • Gandan Jiang
  • Mio Takase
  • Yukine Aihara
  • Hideyuki ShigemoriEmail author


Alzheimer’s diseases (AD) and type 2 diabetes (T2D) are two age-related diseases characterized by amyloid fibrillogenesis. Prevention of amyloid aggregation is a promising therapeutic strategy for AD and T2D. Two spermine alkaloids, kukoamines A and B, isolated from Lycii Cortex (LyC) were investigated for their inhibitory effect on amyloid aggregation. Both kukoamines A and B inhibited aggregation of amyloid β (Aβ) and human islet amyloid polypeptide (hIAPP) in a dose-dependent manner. Kukoamine B showed stronger inhibitory activity than kukoamine A. These results on the inhibitory activity of kukoamines A and B on Aβ and hIAPP indicate that the catechol moiety is essential for inhibition of amyloid aggregation.


Kukoamines A and B Lycii Cortex Amyloid aggregation Alzheimer’s disease Type 2 diabetes 



We are pleased to acknowledge Professor Kazuhiro Irie, Associate Professor Kazuma Murakami, and Dr. Mizuho Hanaki, Graduate School of Agriculture, Kyoto University for preparing Aβ42. We would like to thank Editage ( for English language editing. This work was partially supported by JSPS KAKENHI grant no. JP24580156.

Compliance with ethical standards

Conflict of interest

The authors declare no conflicts of interest.


  1. 1.
    Janson J, Laedtke T, Parisi JE, O’Brien P, Petersen RC, Butler PC (2004) Increased risk of type 2 diabetes in Alzheimer disease. Diabetes 53:474–481CrossRefPubMedGoogle Scholar
  2. 2.
    Flier JS (2004) Obesity wars: molecular progress confronts an expanding epidemic. Cell 116:337–350CrossRefPubMedGoogle Scholar
  3. 3.
    Maher PA, Schubert DR (2009) Metabolic links between diabetes and Alzheimer’s disease. Expert Rev Neurother 9:617–630CrossRefPubMedGoogle Scholar
  4. 4.
    Alzheimer’s Association (2010) Alzheimer’s disease facts and figures. Alzheimers Dement 6:158–194CrossRefGoogle Scholar
  5. 5.
    Alzheimer’s Association (2013) Alzheimer’s disease facts and figures. Alzheimers Dement 9:208–245CrossRefGoogle Scholar
  6. 6.
    Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K (1985) Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci USA 82:42–45CrossRefGoogle Scholar
  7. 7.
    Glenner GG, Wong CW (1984) Alzheimer’s disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 120:885–890CrossRefPubMedGoogle Scholar
  8. 8.
    Cooper GJ, Willis AC, Clark A, Turner RC, Sim RB, Reid KB (1987) Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients. Proc Natl Acad Sci USA 84:8628–8632CrossRefPubMedGoogle Scholar
  9. 9.
    Westermark P, Wernstedt C, Wilander E, Hayden DW, O’Brien TD, Johnson KH (1987) Amyloid fibrils in human insulinoma and islets of Langerhans of the diabetic cat are derived from a neuropeptide-like protein also present in normal islet cells. Proc Natl Acad Sci USA 84:3881–3885CrossRefPubMedGoogle Scholar
  10. 10.
    Johnson KH, O’Brien TD, Hayden DW, Jordan K, Ghobrial HK, Mahoney WC, Westermark P (1988) Immunolocalization of islet amyloid polypeptide (IAPP) in pancreatic beta cells by means of peroxidase-antiperoxidase (PAP) and protein A-gold techniques. Am J Pathol 130:1–8PubMedPubMedCentralGoogle Scholar
  11. 11.
    Andreetto E, Yan LM, Tatarek-Nossol M, Velkova A, Frank R, Kapurniotu A (2010) Identification of hot regions of the Aβ–IAPP interaction interface as high-affinity binding sites in both cross- and self-association. Angew Chem Int Ed Engl 49:3081–3085CrossRefPubMedGoogle Scholar
  12. 12.
    Toyama BH, Weissman JS (2011) Amyloid structure: conformational diversity and consequences. Annu Rev Biochem 80:1–32CrossRefGoogle Scholar
  13. 13.
    Kurochkin IV, Goto S (1994) Alzheimer’s beta-amyloid peptide specifically interacts with and is degraded by insulin degrading enzyme. FEBS Lett 345:33–37CrossRefPubMedGoogle Scholar
  14. 14.
    Miyamae Y, Kurisu M, Murakami K, Han J, Isoda H, Irie K, Shigemori H (2012) Protective effects of caffeoylquinic acids on the aggregation and neurotoxicity of the 42-residue amyloid β-protein. Bioorg Med Chem 20:5844–5849CrossRefPubMedGoogle Scholar
  15. 15.
    Kurisu M, Miyamae Y, Murakami K, Han J, Isoda H, Irie K, Shigemori H (2013) Inhibition of amyloid β aggregation by acteoside, a phenylethanoid glycoside. Biosci Biotech Biochem 77:1329–1332CrossRefGoogle Scholar
  16. 16.
    Kidachi E, Kurisu M, Miyamae Y, Hanaki M, Murakami K, Irie K, Shigemori H (2016) Structure-activity relationship of phenylethanoid glycosides on the inhibition of amyloid β aggregation. Heterocycles 92:1976–1982CrossRefGoogle Scholar
  17. 17.
    Aihara Y, Kawaguchi A, Hanaki M, Murakami K, Irie K, Shigemori H (2017) Inhibitory activity of hispidin derivatives isolated from Inonotus obliquus on amyloid β aggregation. Heterocycles 94:1280–1287CrossRefGoogle Scholar
  18. 18.
    Tsunoda T, Takase M, Shigemori H (2018) Structure-activity relationship of clovamide and its related compounds for the inhibition of amyloid β aggregation. Bioorg Med Chem 26:3202–3209CrossRefPubMedGoogle Scholar
  19. 19.
    Hmidene AB, Hanaki M, Murakami K, Irie K, Isoda H, Shigemori H (2017) Inhibitory activities of antioxidant flavonoids from Tamarix gallica on amyloid aggregation related to Alzheimer’s and type 2 diabetes diseases. Biol Pharm Bull 40:238–241CrossRefPubMedGoogle Scholar
  20. 20.
    Ye Z, Huang Q, Ni HX, Wang D (2008) Cortex Lycii Radicis extracts improve insulin resistance and lipid metabolism in obese-diabetic rats. Phytother Res 22:1665–1670CrossRefPubMedGoogle Scholar
  21. 21.
    Yao X, Peng Y, Xu LJ, Li L, Wu QL, Xiao PG (2011) Phyto-chemical and biological studies of Lycium medicinal plants. Chem Bio Divers 8:976–1010Google Scholar
  22. 22.
    Hu XL, Gao LY, Niu YX, Tian X, Wang J, Meng WH, Zhang Q, Cui C, Han L, Zhao QC (2015) Neuroprotection by kukoamine A against oxidative stress may involve N-methyl-D-aspartate receptors. Biochim Biophys Acta 1850:287–298CrossRefPubMedGoogle Scholar

Copyright information

© The Japanese Society of Pharmacognosy 2019

Authors and Affiliations

  1. 1.Graduate School of Life and Environmental SciencesUniversity of TsukubaTsukubaJapan
  2. 2.Faculty of Life and Environmental SciencesUniversity of TsukubaTsukubaJapan

Personalised recommendations